Chemical and technological delivery systems for idebenone: a review of literature production

被引:18
作者
Carbone, Claudia [2 ]
Pignatello, Rosario [2 ]
Musumeci, Teresa [2 ]
Puglisi, Giovanni [1 ,2 ]
机构
[1] Univ Catania, Dept Drug Sci, I-95125 Catania, Italy
[2] Univ Catania, Dipartimento Sci Farm, Sez Tecnol Farmaceut, I-95125 Catania, Italy
关键词
antioxidant activity; cyclodextrins; drug delivery systems; lipoamino acids; liposomes; microemulsions; nanoparticles; prodrugs; SLN; solid lipid nanoparticles; SOLID LIPID NANOPARTICLES; ETHANOL-INDUCED INJURY; IN-VITRO EVALUATION; DRUG-DELIVERY; BRAIN MITOCHONDRIA; PEROXIDATION; INHIBITION; THERAPY; MODEL; STABILITY;
D O I
10.1517/17425247.2012.724396
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Idebenone (IDE) is an antioxidant compound, structurally related to coenzyme Q10. Its therapeutic potential is growing in different application areas, as demonstrated by the number of experimental works and patents produced in very recent years. Areas covered: Cyclodextrin inclusion complexes, liposomes, microemulsions, prodrugs, polymeric and lipid nanoparticles have been explored to achieve different goals, such as topical administration, brain targeting or increasing the bioavailability of this highly lipophilic drug. This review summarizes the results of works published in the last 20 years for the delivery and targeting of this drug. Expert opinion: A direct comparison of the different carrier systems is not easy and could not even be significant, due to the large variables existing among them. However, the different forms of delivery can help increase idebenone solubility, stability and biochemical activity. Further studies will be developed in order to improve the controlled release and targeting of idebenone.
引用
收藏
页码:1377 / 1392
页数:16
相关论文
共 60 条
[1]   Antioxidant idebenone-loaded nanoparticles based on chitosan and N-carboxymethylchitosan [J].
Amorim, Clarissa de M. ;
Couto, Angelica G. ;
Netz, Daisy J. A. ;
de Freitas, Rilton A. ;
Bresolin, Tania M. B. .
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2010, 6 (06) :745-752
[2]  
[Anonymous], 2012, CLINICALTRIALS GOV S
[3]  
[Anonymous], 2012, EFF TOL ID BOYS CARD
[4]  
[Anonymous], 2012, STUD ID TREATM MIT E
[5]  
[Anonymous], EMEA872462009
[6]  
[Anonymous], 2012, DOUBL BLIND PLAC CON
[7]   Pharmacokinetic evaluation of idebenone [J].
Becker, Claudia ;
Bray-French, Katharine ;
Drewe, Juergen .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2010, 6 (11) :1437-1444
[8]   Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: Results from a 12 month, double-blind, randomized placebo-controlled trial [J].
Buyse, Gunnar M. ;
Goemans, Nathalie ;
van den Hauwe, Marleen ;
Thijs, Daisy ;
de Groot, Imelda J. M. ;
Schara, Ulrike ;
Ceulemans, Berten ;
Meier, Thomas ;
Mertens, Luc .
NEUROMUSCULAR DISORDERS, 2011, 21 (06) :396-405
[9]  
Cannava` C, 2012, J INCLUSION IN PRESS
[10]   Idebenone Treatment In Leber's Hereditary Optic Neuropathy [J].
Carelli, Valerio ;
La Morgia, Chiara ;
Valentino, Maria Lucia ;
Rizzo, Giovanni ;
Carbonelli, Michele ;
De Negri, Anna Maria ;
Sadun, Federico ;
Carta, Arturo ;
Guerriero, Silvana ;
Simonelli, Francesca ;
Sadun, Alfredo Arrigo ;
Aggarwal, Divya ;
Liguori, Rocco ;
Avoni, Patrizia ;
Baruzzi, Agostino ;
Zeviani, Massimo ;
Montagna, Pasquale ;
Barboni, Piero .
BRAIN, 2011, 134